天津医药
天津醫藥
천진의약
TIANJIN MEDICAL JOURNAL
2015年
9期
1030-1033
,共4页
癌,非小细胞肺%化学疗法,辅助%无病生存%Kaplan-Meiers评估%基因检测%个体化治疗
癌,非小細胞肺%化學療法,輔助%無病生存%Kaplan-Meiers評估%基因檢測%箇體化治療
암,비소세포폐%화학요법,보조%무병생존%Kaplan-Meiers평고%기인검측%개체화치료
carcinoma,non-small-cell lung%chemotherapy,adjuvant%disease-free survival%Kaplan-Meiers estimate%genetic testing%individualized chemotherapy
目的：探讨以基因检测为指导的非小细胞肺癌（NSCLC）术后个体化治疗的效果。方法将接受全胸腔镜肺癌根治术的Ⅱ、ⅢA期NSCLC患者56例随机分为个体化治疗组26例和非个体化治疗组30例，取个体化治疗组患者新鲜肿瘤组织进行基因检测，检测靶标包括切除修复交叉互补复合体1(ERCC1)、核苷酸还原酶亚单位1(RRM1)、β微管蛋白Ⅲ、胸苷酸合成酶(TS)、表皮生长因子受体(EGFR)、乳腺癌敏感蛋白1（BRCA1）等。个体化治疗组根据检测结果制定化疗方案，非个体化治疗组采用“吉西他滨+顺铂”方案，比较2组1年、2年无疾病生存率（DFS）、疾病无进展生存期(PFS)和总生存期(OS)。结果个体化治疗组2年DFS（57.69%）、PFS（月：22.1±5.0）和OS（月：24.1±3.2）均高于非个体化治疗组（分别是30.00%、18.9±6.2、21.9±4.3，均P<0.05）；2组1年DFS（88.46%vs 83.33%）差异无统计学意义。结论基于基因检测的个体化治疗可以提高NSCLC术后的2年DFS、PFS和OS，提高化疗的有效率。
目的：探討以基因檢測為指導的非小細胞肺癌（NSCLC）術後箇體化治療的效果。方法將接受全胸腔鏡肺癌根治術的Ⅱ、ⅢA期NSCLC患者56例隨機分為箇體化治療組26例和非箇體化治療組30例，取箇體化治療組患者新鮮腫瘤組織進行基因檢測，檢測靶標包括切除脩複交扠互補複閤體1(ERCC1)、覈苷痠還原酶亞單位1(RRM1)、β微管蛋白Ⅲ、胸苷痠閤成酶(TS)、錶皮生長因子受體(EGFR)、乳腺癌敏感蛋白1（BRCA1）等。箇體化治療組根據檢測結果製定化療方案，非箇體化治療組採用“吉西他濱+順鉑”方案，比較2組1年、2年無疾病生存率（DFS）、疾病無進展生存期(PFS)和總生存期(OS)。結果箇體化治療組2年DFS（57.69%）、PFS（月：22.1±5.0）和OS（月：24.1±3.2）均高于非箇體化治療組（分彆是30.00%、18.9±6.2、21.9±4.3，均P<0.05）；2組1年DFS（88.46%vs 83.33%）差異無統計學意義。結論基于基因檢測的箇體化治療可以提高NSCLC術後的2年DFS、PFS和OS，提高化療的有效率。
목적：탐토이기인검측위지도적비소세포폐암（NSCLC）술후개체화치료적효과。방법장접수전흉강경폐암근치술적Ⅱ、ⅢA기NSCLC환자56례수궤분위개체화치료조26례화비개체화치료조30례，취개체화치료조환자신선종류조직진행기인검측，검측파표포괄절제수복교차호보복합체1(ERCC1)、핵감산환원매아단위1(RRM1)、β미관단백Ⅲ、흉감산합성매(TS)、표피생장인자수체(EGFR)、유선암민감단백1（BRCA1）등。개체화치료조근거검측결과제정화료방안，비개체화치료조채용“길서타빈+순박”방안，비교2조1년、2년무질병생존솔（DFS）、질병무진전생존기(PFS)화총생존기(OS)。결과개체화치료조2년DFS（57.69%）、PFS（월：22.1±5.0）화OS（월：24.1±3.2）균고우비개체화치료조（분별시30.00%、18.9±6.2、21.9±4.3，균P<0.05）；2조1년DFS（88.46%vs 83.33%）차이무통계학의의。결론기우기인검측적개체화치료가이제고NSCLC술후적2년DFS、PFS화OS，제고화료적유효솔。
Objective To explore the efficiency of postoperative individualized chemotherapy based on genetic testing results for non-small cell lung cancer (NSCLC). Methods Fifty-six NSCLC patients at stageⅡorⅢA who accepted video-assisted thoracic operation were divided into two groups:the individualized chemotherapy group (n=26) and non individual?ized chemotherapy group (n=30). The fresh lung tumor tissue of individualized chemotherapy group was tested target gene,in?cluding excision repair cross complementing 1 (ERCC1),ribonucleotide reductase subunit M1 (RRM1),β-tubulinⅢ,thymi?dylate synthase(TS),epidermal growth factor receptor (EGFR) and breast cancer gene 1 (BRCA1). The theraputic plan was based on genetic testing results in individualized chemotherapy group, and the non individualized chemotherapy group re?ceiving gemcitabine plus cisplatin. The 1-year disease free survival (DFS), 2-year disease free survival (DFS), the progres?sion-free survival (PFS) and the overall survival (OS) were compared between two groups. Results The 2-year DFS (57.69%), PFS (22.1 ± 5.0 months) and OS (24.1 ± 3.2 months) were significantly higher in the individualized chemotherapy group than those of non individualized chemotherapy group (respectively 30.00%, 18.9 ± 6.2 months, 21.9 ± 4.3 months, P<0.05). There was no significant difference in 1-year DFS between two groups (88.46%vs 83.33%, P<0.05). Conclusion The individualized chemotherapy based on genetic testing results can enhance the 2-year DFS, PFS, OS and the efficiency of postoperative adjuvant chemotherapy for NSCLC.
